<DOC>
	<DOC>NCT00922090</DOC>
	<brief_summary>The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.</brief_summary>
	<brief_title>A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosed as Schizophrenia according to DSMIVTR criteria Patients who are taking Seroquel XR no longer than 1 month Patients who get antipsychotics monotherapy at least 1 week before enroll in this study First episode, drug naive schizophrenic subjects. Meeting the criteria for any other (than schizophrenia) DSMIV Axis I diagnosis,concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation. Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Seroquel XR</keyword>
	<keyword>CGI-CB</keyword>
	<keyword>SWN-K</keyword>
</DOC>